Also known as: AASLD
Sagimet Biosciences reported fourth quarter and full year 2025 financial results, announcing plans to initiate a Phase 2 trial of denifanstat and resmetirom combination in F4 MASH patients in the second half of 2026, with a 26-week biomarker readout expected in the first half of 2028.
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07382349 |
A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease |
NOT_YET_RECRUITING | NA |
| NCT07046429 |
Affect of Melatonin on Sleep and Cognition in Cirrhosis |
RECRUITING | NA |
| NCT04953143 |
LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease |
COMPLETED | NA |
| NCT04899115 |
VE303 for Treatment of Hepatic Encephalopathy (HE) |
COMPLETED | PHASE2 |
| NCT04642391 |
Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis |
COMPLETED | |
| NCT04218695 |
Prophylactic Antibiotics in Admitted Cirrhotics |
COMPLETED | PHASE4 |
| NCT03839082 |
Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease |
COMPLETED | NA |
| NCT03602976 |
Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis |
TERMINATED | PHASE2 |
| NCT00570960 |
Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis |
TERMINATED | PHASE4 |
